ARS Pharmaceuticals Inc

ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ARS Pharmaceuticals advances neffy launch amidst financial challenges

ARS Pharmaceuticals made notable progress with neffy's approval and launch, though facing financial challenges in Q3.
Strengths lie in positive feedback, strategic partnerships, and opportunities for expansion and market penetration.
Challenges include financial losses, revenue recognition complexities, and meeting commercial coverage targets.
Opportunities abound in global expansion, diverse market interest, and potential for accelerated launch plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc. And Affected Investors Are Encouraged To Join

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc. And Harmed Investors Are Encouraged To Join

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc. Is Being Investigated By The Schall Law Firm, And Affected Investors Are Urged To Engage In Dialogue

LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Begin Discussions

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate Dialogue

ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript

Alto Neuroscience Inc

Atlas Lithium Inc

Krispy Kreme

Amicus Therapeutics

Are you looking for low-cost stocks to add to your portfolio?

5 Stocks Under $10 Growing 50% Or More

Good news for those who suffer from severe allergic reactions: a nasal spray containing epinephrine rather than a needle can now treat those frightening moments.

EpiPen gets a new competitor: FDA approves anaphylaxis nasal spray

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Under The Schall Law Firm's Probe And Affected Investors Are Encouraged To Begin Conversations

Neffy is expected to be available in the United States within eight weeks of FDA approval, the company said.

Nasal spray alternative to EpiPen for allergic reactions approved by FDA

neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

The U.S. Food and Drug Administration said on Friday it had approved ARS Pharmaceuticals' nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions.

US FDA approves first nasal spray for allergic reactions

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Being Investigated By The Schall Law Firm And Impacted Investors Are Urged To Initiate Dialogue

ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm, And Impacted Investors Are Encouraged To Initiate Dialogue

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024.

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.18 per share a year ago.

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Investigated By The Schall Law Firm And Impacted Investors Urged To Engage In Dialogue

neffy ® (epinephrine nasal spray) New Drug Application (NDA) under review by FDA; discussions are ongoing to finalize labeling with FDA; PDUFA date in early October 2024

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc And Urges Affected Investors To Start Conversations

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Is Under Examination By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Affected Investors To Start Conversation, ARS Pharmaceuticals Inc Is Under Scrutiny

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for ARS Pharmaceuticals Inc Stock (SPRY)